Sleep disturbances: Core symptoms of major depressive disorder rather than associated or comorbid disorders

World Journal of Biological Psychiatry

Volumn 10, Issue 4, 2009, Pages 269-275

  Mendlewicz, Julien ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

Antidepressants; Major depressive disorder; Management; Residual symptoms; Sleep disturbances

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; AMITRIPTYLINE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; REBOXETINE; SERTRALINE; TIANEPTINE; TRANYLCYPROMINE; TRAZODONE; VALPROIC ACID; VENLAFAXINE;

BODY MASS; COMORBIDITY; DRUG WITHDRAWAL; HUMAN; HYPERSOMNIA; INSOMNIA; MAJOR DEPRESSION; REVIEW; SIDE EFFECT; SLEEP DISORDER; SLEEP PATTERN; SOMNOLENCE;

ACETAMIDES; ADRENERGIC ALPHA-ANTAGONISTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPNOTICS AND SEDATIVES; RECURRENCE; SLEEP DISORDERS; SLEEP INITIATION AND MAINTENANCE DISORDERS; SLEEP STAGES; SLEEP, REM;

EID: 70450190023     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970802503086     Document Type: Review

References (52)

1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TH, Bryson H for the ESEMeD/MHEDEA et al. 2000. Investigators. 2004. Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 420, 21-27.
2. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. 4th edn. Washington, DC: American Psychiatric Association.
3. Anderson IM. 2000. Selective serotonin reuptake inhibitors vs. tricyclic antidepressants: a meta-analysis of efficacy and toler-ability. J Affect Disord 58:19-36.
4. Armitage R, Hoffmann RF. 2001. Sleep EEG, depression and gender. Sleep Med Rev 5:237-246.
5. Armitage R. 1995. Microarchitectural findings in sleep EEG in depression: diagnostic implications. Biol Psychiatry 37(2): 72-84.
6. Armitage R. 2000. The effects of antidepressants on sleep in patients with depression. Can J Psychiatry 45:803-809.
7. Armstrong SM, McNulty OM, Guardiola-Lemaitre B, Redman JR. 1993. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol Biochem Behav 46:45-49
8. Berger M, Riemann D. 1993. REM sleep in depression-An overview. J Sleep Res 2(4):211-223.
9. Biglia N, Kubatzki F, Sgandurra P, Ponzone R, Marenco D, Peano E, et al. 2007. Mirtazapine for the treatment of hot flushes in breast cancer survivors: a prospective pilot trial. Breast J 13(5):490-495
10. Breslau N, Roth T, Rosenthal L, Andreski P. 1996. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 39:411-418
11. Fava GA, Grandi S, Canestrari R, Molmar G. 1990. Prodromal symptoms in primary major depressive disorder. J Affect Disord 19:149-152.
12. Fava M. 2004. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry 65(Suppl 16):27-32.
13. Ford DE, Kamerow DB. 1989. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? J Am Med Assoc 262:1479-1484.
14. Gallup Organization. 1991. Sleep in America. Princeton, NJ: the Gallup Organization.
15. Gruenberg AM, Goldstein RD. 2003. Mood disorders: depression. In: Tasman A, Kay J, Lieberman JA Psychiatry. 2nd ed. Chichester: John Wiley & Sons. p 1207-1236.
16. Guilleminault C. 2005. Agomelatine versus venlafaxine on subjective sleep of patients with major depression disorder. Eur Neuropsychopharmacology 15(Suppl 3):S419.
17. Hamilton M. 1960. A rating scale for depression. The Hamilton Depression Rating Scale (HDRS). J Neurol Neurosurg Psychiatry 23:56-62.
18. Hannan N, Hamzah Z, Akinpeloye HO, Meagher D. 2007. Venlafaxine- mirtazapine combination in the treatment of persistent depressive illness. J Psychopharmacol 21(2):161-164.
19. Kennedy SH, Emsley R. 2006. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsy 16:93-100.
20. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas AR, et al. 2003. The epidemiology of major depressive disorder. Results from the National Comorbidity Survey Replication (NCS-R). J Am Med Assoc 289:3095-3105.
21. Kirsch I, Moore TJ, Scoboria A, Nicholls SS. 2002. The Emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevent Treat 5:23.
22. Krauchi K, Cajochen C, Mori D, Graw P, Wirz-Justice A. 1997. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 272:R1178-1188.
23. Kupfer DJ, Ehlers CL, Frank E, Grochocinski VJ, McEachran AB, et al. 1991. EEG sleep profile and recurrent depression. BiolPsychiatry 30:641-655.
24. Kupfer DJ, Frank E, McEachran AB, Grochocinski VJ. 1990. Delta sleep ratio. A biological correlate of early recurrence in unipolar affective disorder. Arch Gen Psychiatry 47:1100-1105.
25. Lemoine P, Nicolas A. 2007. Depression and sleep. World Psychiatr Assoc Bull Depress 11(33):2-3.
26. Leproult R, Van Onderbergen A, L'hermite-Baleriaux M, Van Cauter E, Copinschi G. 2005. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol 63:298-304.
27. Loo H, Hale A, D'Haenen H. 2002. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 17:239-247.
28. Martinet L, Guardiola-Lemaitre B, Mocaer E. 1996. Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol Biochem Behav 54:713-718.
29. McIntyre RS, O'Donovan C. 2004. The human cost of not achieving full remission in depression. Can J Psychiatry 49(3 Suppl 1):10-16.
30. Mendlewicz J, Kerkhofs M. 1991. Sleep electroencephalography in depressive illness. A collaborative study by the World Health Organization. Br J Psychiatry 159:505-509.
31. Millan MJ, Brocco M, Gobert A, Dekeyne A. 2005. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berlin) 177:448-458
32. Montgomery SA, Asberg M. 1979. Montgomery-Asberg Depression Rating Scale (MADRS). Br J Psychiatry 134:382-389.
33. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. 2004. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 19:271-280.
34. Monti JM. 1989. Effect of a reversible monoamine oxidase 6a inhibitor on sleep of depressed patients. Br J Psychiatry Suppl 6:61-65.
35. Mrakotsky C, Masek B, Biederman J, Raches D, Hsin O, Forbes P, et al. 2008. Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia. J Anxiety Disord 22(1):88-97.
36. Nofzinger EA, Nichols TE, Meltzer CC, Price J, Steppe DA, Miewald JM, et al. 1999. Changes in forebrain function from waking to REM sleep in depression: preliminary analyses of 18FFDG PET studies. Psychiatry Res 91:59-78.
37. Paykel ES, Brugha E, Frayers E. 2005. Size and burden off depressive disorders in Europe. Eur Neuropsychopharmacol 15:411-423
38. Ohayon M, Roth T 2003. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 37:9-15.
39. Perlis ML, Giles DE, Buysse DJ, Tu X, Kupfer DJ. 1997. Self-reported sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord 42:209-212.
40. Quera Salva MA, Vanier B, Chapotot F, Bohic M, Andre S, Moulin C, et al. 2005. Effect of agomelatine on the sleep EEG in patients with major depressive disorder. Eur Neuropsychopharmacol 15(Suppl 3):S435.
41. Quera-Salva MA, Vanier B, Laredo J, Hartley S, Chapotot F, Moulin C, et al. 2007. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 10(5):691-696.
42. Douery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al. 2007. Group for the Study of Resistant Depression. Clinical factors associated with treatment resistant in major Depressive Disorder: results from a European multicenter. J Clin Psychiatry 7:1062-1070.
43. Rush AJ, Trivedi MH, Wisniewski S.R. 2006. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New Eng J Med 354:1231-1242.
44. Schüle C, Baghai TC, Eser D, Hecht S, Hermisson I, Born C, et al. 2007. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. World J Biol Psychiatry 8(2):112-122.
45. Sonawalla SB, Fava M. 2005. Severe depression: is there a best approach? CNS Drugs 15:765-776.
46. Storosum JG, Elferink AJ, van Zwieten BJ, van den Brink W, Gersons BP, van Strik R, et al. 2001. Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. Eur Neuropsychopharmacol 11:173-180.
47. Thase ME. 1999. Antidepressant treatment of the depressed patients with insomnia. J Clin Psychiatry 60(Suppl 17):28-31.
48. Thase ME. 2003. Achieving remission and managing relapse in depression. J Clin Psychiatry 64(Suppl 18):3-7.
49. Trivedi MH, Fava M, Wisniewski SR. 2006. Medication augmentation after the failure of SSRIs for depression. New Eng J Med 354:243-1252.
50. Tsuno N, Besset A. 2005. Sleep and depression. J Clin Psychiatry 66:1254-1269.
51. Wilson S, Argyropoulos S. 2005. Antidepressants and sleep. A qualitative review of the literature. Drugs 65(7):927-947.
52. Yous S, Andrieux J, Howell HE, Morgan PJ, Renard P, Pfeiffer B, et al. 1992. Novel napthalenic ligands with high affinity for the melatonin receptor. J Med Chem 35:1484-1486.